Galmed Pharmaceuticals Ltd (GLMD)
Galmed Pharmaceuticals Ltd. is a biopharmaceutical company focused on developing therapies for liver diseases. Its lead candidate, Aramchol, is a synthetic fatty acid-bile acid conjugate molecule being studied in Phase III for oral treatment of non-alcoholic steatohepatitis (NASH) in overweight or obese patients with prediabetes or type II diabetes. The company is also evaluating Aramchol in the ARRIVE Phase IIa study for HIV-associated non-alcoholic fatty liver disease and lipodystrophy. Beyond Aramchol, Galmed is developing Amilo-5MER, a synthetic peptide, and MyBiotics, which is in pre-clinical testing for NASH and fibrosis. The company has a commercialization license agreement with Samil Pharma for Aramchol in South Korea and a collaboration with OnKai related to its AI platform. Galmed Pharmaceuticals was founded in 2000 and is headquartered in Ramat Gan, Israel.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Book Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-GLMD
|
$5.32
|
32.0% Upside
|
Undervalued
|
Not available
|
Not available
|
Fair
|
0.0%
|
November 25, 2026
|
0.3x
|
4.036 M
|
-7.066 M
|
3.1%
|
97.3%
|
-54.2
|
75.3%
|
